QLS7305 / Qilu Pharma - LARVOL DELTA

Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P2 trial • Complement-mediated Rare Disorders • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Renal Disease